

---

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM S-1

### REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

---

## PACIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**2834**  
(Primary Standard Industrial  
Classification Code Number)

**51-0619477**  
(I.R.S. Employer  
Identification Number)

**5 Sylvan Way, Suite 100**  
**Parsippany, New Jersey 07054**  
**(973) 254-3560**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**David M. Stack**  
**President and Chief Executive Officer**  
**5 Sylvan Way, Suite 100**  
**Parsippany, New Jersey 07054**  
**(973) 254-3560**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

#### Copies to:

**Joseph K. Wyatt, Esq.**  
Wilmer Cutler Pickering Hale and Dorr LLP  
950 Page Mill Road  
Palo Alto, California 94304  
(650) 858-6000

**Marc D. Jaffe Esq.**  
**Gregory P. Rodgers, Esq.**  
Latham & Watkins LLP  
885 Third Avenue  
New York, NY 10022  
(212) 906-1200

---

**Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  333-177776

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

**CALCULATION OF REGISTRATION FEE**

Title of each class of securities to be registered	Amount to be registered (1)	Proposed maximum offering price per share (2)	Proposed maximum aggregate offering price (2)	Amount of registration fee
Common Stock, \$0.001 par value per share	1,150,000 shares	\$ 6.50	\$ 7,475,000	\$ 857

(1) Includes 150,000 shares which the Underwriters have the option to purchase from the Company to cover over-allotments, if any.

(2) Estimated in accordance with Rule 457(a) of the Securities Act of 1933.

**This Registration Statement shall become effective upon filing with the Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.**

---

---

---

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This registration statement is being filed with respect to the registration of additional shares of common stock, par value \$0.001 per share, of Pacira Pharmaceuticals, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-177776) filed by Pacira Pharmaceuticals, Inc., which was declared effective by the Commission on November 15, 2011, are incorporated in this registration statement by reference.

The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Parsippany, State of New Jersey, on this 15<sup>th</sup> day of November, 2011.

Pacira Pharmaceuticals, Inc.

By:           /s/ David Stack            
 David Stack  
 President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
<u>          /s/ David Stack          </u> David Stack	Director, President and Chief Executive Officer (Principal Executive Officer)	November 15, 2011
<u>          /s/ James Scibetta          </u> James Scibetta	Chief Financial Officer (Principal Financial and Accounting Officer)	November 15, 2011
<u>  *</u> Fred Middleton	Director	November 15, 2011
<u>  *</u> Luke Evnin	Director	November 15, 2011
<u>  *</u> Laura Brege	Director	November 15, 2011
<u>  *</u> John Longenecker	Director	November 15, 2011
<u>  *</u> Gary Pace	Director	November 15, 2011
<u>  *</u> Andreas Wicki	Director	November 15, 2011
<u>  *</u> Paul Hastings	Director	November 15, 2011

\*By:           /s/ David Stack            
 David Stack  
 Attorney-in-Fact

## EXHIBIT INDEX

Exhibit No.	Description
5.1	Opinion of Wilmer Cutler Pickering Hale and Dorr LLP
23.1	Consent of Wilmer Cutler Pickering Hale and Dorr LLP (Included in Exhibit 5.1)
23.2	Consent of J.H. Cohn LLP
24.1*	Powers of Attorney

---

\* Filed as Exhibit 24.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-177776) filed with the Commission on November 7, 2011, as amended, and incorporated in this registration statement by reference.

WILMERHALE

Joseph K. Wyatt

+1 650 858 6016(t)

+1 650 858 6100(f)

joe.wyatt@wilmerhale.com

November 15, 2011

Pacira Pharmaceuticals, Inc.  
5 Sylvan Way, Suite 100  
Parsippany, New Jersey 07054

Registration Statement on Form S-1

Ladies and Gentlemen:

This opinion is furnished to you in connection with a Registration Statement on Form S-1 (File No. 333- ) (the "Registration Statement") filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Rule 462(b) of the Securities Act, for the registration of 1,150,000 shares of Common Stock, \$0.001 par value per share (the "Shares"), of Pacira Pharmaceuticals, Inc., a Delaware corporation (the "Company"), including 150,000 Shares issuable upon exercise of an over-allotment option granted by the Company.

The Shares are to be sold by the Company pursuant to an underwriting agreement (the "Underwriting Agreement") to be entered into by and among the Company and Barclays Capital Inc. and Jefferies & Company, Inc., as representatives of the several underwriters named in the Underwriting Agreement, the form of which has been filed as Exhibit 1.1 to the Registration Statement.

We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us by the Company, the Certificate of Incorporation and By-Laws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.

Wilmer Cutler Pickering Hale and Dorr LLP, 950 Page Mill Road, Palo Alto, CA 94304

Beijing Berlin Boston Brussels Frankfurt London Los Angeles New York Oxford Palo Alto Waltham Washington

We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the State of California, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and nonassessable.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related Prospectus under the caption "Validity of Common Stock." In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

WILMER CUTLER PICKERING  
HALE AND DORR LLP

By: /s/ Joseph K. Wyatt  
Joseph K. Wyatt, a Partner



**Consent of Independent  
Registered Public Accounting Firm**

We consent to incorporation by reference in this Registration Statement on Form S-1MEF of Pacira Pharmaceuticals, Inc. of our report, dated March 31, 2011, on our audits of the consolidated financial statements of Pacira Pharmaceuticals, Inc. as of December 31, 2010 and 2009, and for each of the three years in the period ended December 31, 2010. We also consent to the reference to our firm under the caption "Experts" in the prospectus incorporated by reference into this Registration Statement.

/s/ J.H. Cohn LLP

Roseland, New Jersey  
November 15, 2011

---